Biodistribution Studies for Novel Cell-Based Therapies (NK, iPSC) in the San Francisco Bay Area

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Biodistribution Studies for Novel Cell-Based Therapies (NK, iPSC) in the San Francisco Bay Area

Biodistribution Studies for Novel Cell-Based Therapies (NK, iPSC)

CELL & GENE | RNA | BIOLOGICS

Biodistribution studies for cell-based therapies, including Natural Killer (NK) and induced pluripotent stem cell (iPSC) derived constructs, are a core component of a successful Investigational New Drug (IND) application. These assessments define the in vivo kinetics, persistence, and potential for non-target tissue biodistribution, directly informing the safety and efficacy profile. Franklin Biolabs provides GxP-compliant biodistribution programs specifically designed for the complexities of cellular therapeutics, leveraging quantitative PCR (qPCR), droplet digital PCR (ddPCR), and advanced histology to generate regulatory-ready data packages. Our programs are supported by a >100,000 sq ft facility designed for advanced therapeutic modalities.

What are the primary quantitative methods for tracking NK and iPSC-derived cells in vivo?

We primarily utilize qPCR and ddPCR to quantify vector or cell-specific DNA sequences in collected tissues. This approach provides sensitive and specific data on cell persistence and distribution. The choice between qPCR and ddPCR depends on the need for absolute versus relative quantification and the expected copy number in target tissues.

How do you ensure the selected cell label or reporter gene does not alter cell function?

Prior to initiating an in vivo study, we perform comprehensive in vitro characterization. This includes assessing the stability of the label over multiple cell divisions and confirming that key functional attributes (e.g., cytotoxicity for NK cells, differentiation potential for iPSCs) remain unchanged post-labeling. This aligns with established principles in gene transfer, where reporter expression must be carefully validated.

Can your histology methods differentiate between viable and non-viable therapeutic cells?

Yes. Our histology core combines standard H&E staining with advanced techniques like immunohistochemistry (IHC) and in situ hybridization (ISH). These methods can be targeted to markers of cell viability, apoptosis (e.g., cleaved caspase-3), or cell-specific proteins, providing spatial context to the quantitative data from PCR analysis.

What logistical support is available for managing sample integrity?

We provide dedicated logistical support and scientific project management for all partners. Our operational framework is built to manage sample stability and transport, ensuring data integrity for complex preclinical programs.

Defining the In Vivo Fate of Cellular Therapeutics

A well-designed biodistribution study provides a clear understanding of a cell therapy’s behavior following administration. For NK and iPSC-derived platforms, this involves tracking their migration to target tissues, their persistence over time, and their clearance from circulation. This dataset is fundamental to building the safety narrative for regulatory submissions.

Our approach integrates multiple analytical techniques to build a comprehensive profile:

  • Quantitative Biodistribution: Using qPCR and ddPCR to determine the quantity of therapeutic cells in a wide range of tissues.

  • Cellular Localization: Employing advanced histology and imaging to visualize the precise location of cells within tissue microenvironments.

  • Persistence and Clearance: Establishing a time-course assessment to model the kinetics of the cell therapy product in vivo.

A 3D rendering of Y-shaped antibody molecules against a blue, abstract background.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Methodological Considerations for Advanced Modalities

The selection of analytical methods is determined by the therapeutic construct. The choice of a reporter system, for instance, requires careful consideration to ensure it accurately reflects cell location without interfering with biological function. As demonstrated in AAV-based gene transfer analyses, different reporters can yield distinct expression profiles, underscoring the need for vector- and tissue-specific validation (PMID: 17510373).

Similarly, understanding the host response is a key component of the safety assessment. While the goal is therapeutic action, characterizing any unintended biological effects is a regulatory expectation. Studies evaluating novel AAV vectors have shown that different constructs can elicit varied immune responses, highlighting the importance of characterizing the complete biological outcome of a new therapeutic platform (PMID: 17715240). This principle directly applies to allogeneic cell therapies, where monitoring the host immune reaction is part of a complete safety profile.

<p style=”text-align: center; font-size: 0.

From Preclinical Data to IND Submission

The data generated from these studies directly supports the pharmacology and toxicology sections of an IND filing. A robust data package enables a clear, defensible position on the safety of a novel cell therapy. Franklin Biolabs has a demonstrated history of supporting successful IND applications, with a 100% success rate for programs initiated since 2019. (The Franklin Biolabs brand launched in 2024.) Our scientific and regulatory expertise helps sponsors navigate the path from late-stage preclinical development to clinical trials, typically within an 18-24 month IND timeline.

We are committed to the highest standards of animal welfare in all in vivo programs. Study designs incorporate the principles of the 3Rs (Replacement, Reduction, and Refinement) to ensure ethical and scientifically sound data generation.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities